...
首页> 外文期刊>Eye >Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.
【24h】

Therapeutic effect of bevacizumab injected into the silicone oil in eyes with neovascular glaucoma after vitrectomy for advanced diabetic retinopathy.

机译:玻璃体切除术后贝伐珠单抗注入硅油治疗新生血管性青光眼对晚期糖尿病性视网膜病变的治疗作用。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the effect of intra-silicone injection of bevacizumab for the treatment of neovascular glaucoma (NVG) after vitrectomy for advanced proliferative diabetic retinopathy. METHODS: Bevacizumab was injected into the silicone oil in five pseudophakic eyes of five patients with NVG. The iris neovascularization (INV) and NVG had developed 1.5-4 months after vitrectomy and silicone oil tamponade. The main outcome measures were regression of INV, intraocular pressure and visual acuity. RESULTS: In all eyes, INV regressed and intraocular pressure was controlled within 7 days. Visual acuity improved in all eyes. In one patient, INV and NVG recurred 10 weeks after the injection and was successfully treated with a repeat intra-silicone bevacizumab injection. CONCLUSION: Intra-silicone injection of bevacizumab is effective in the treatment of patients with INV and NVG after vitrectomy for advanced proliferative diabetic retinopathy.
机译:目的:评估贝伐单抗的硅酮注射治疗玻璃体切除术后晚期增生性糖尿病视网膜病变的新生血管性青光眼(NVG)的效果。方法:在5例NVG患者的5只假晶状体眼中,将贝伐单抗注射到硅油中。虹膜新血管形成(INV)和NVG在玻璃体切除术和硅油填塞后1.5-4个月出现。主要结局指标为INV下降,眼压和视力。结果:在所有的眼睛中,INV退化并且眼内压在7天内得到控制。改善所有人的视力。在一名患者中,注射后10周,INV和NVG复发,并通过重复的硅胶内贝伐单抗注射成功治疗。结论硅酮注射贝伐单抗可有效治疗晚期增生性糖尿病性视网膜病变玻璃体切除后的INV和NVG患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号